EquityZen Growth Technology Fund LLC - Series 2094
Raised
$1M
Investors
11
Min Invest
$10,038
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2094 is a Delaware-domiciled pooled investment fund filed by EquityZen Advisors LLC and Phil Haslett under Rule 506(b) and Section 3(c). The vehicle raised $1.4M from 11 investors with a $10K minimum investment. It is part of the EquityZen platform, which operates nearly 1,900 pre-IPO SPV and fund entities.
This pre-IPO pooled fund uses the standard 506(b) private placement exemption with a retail-accessible $10K minimum, consistent with EquityZen's platform model of democratizing access to private company shares. The raise size and investor count align with typical single-company or small-portfolio SPVs in the pre-IPO secondary market.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
